S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom

Erasca (ERAS) Stock Forecast & Price Target

$1.84
-0.09 (-4.66%)
(As of 04/17/2024 ET)

Erasca Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$7.83
325.72% Upside
High Forecast$11.00
Average Forecast$7.83
Low Forecast$6.00
TypeCurrent Forecast
4/19/23 to 4/18/24
1 Month Ago
3/20/23 to 3/19/24
3 Months Ago
1/19/23 to 1/19/24
1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.83$8.00$9.50$11.33
Predicted Upside325.72% Upside258.57% Upside237.53% Upside218.35% Upside
Get Erasca Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.

ERAS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ERAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Erasca Stock vs. The Competition

TypeErascaMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside325.72% Upside926.66% Upside12.24% Upside
News Sentiment RatingNegative News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$6.00 ➝ $7.00+215.31%
3/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Maldonado
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00+288.35%
3/11/2024Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Quibria
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$8.00+250.88%
1/5/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$11.00 ➝ $6.00+177.78%
11/29/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+270.37%
6/6/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$20.00 ➝ $11.00+233.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:57 AM ET.

ERAS Price Target - Frequently Asked Questions

What is Erasca's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Erasca stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for ERAS. The average twelve-month price prediction for Erasca is $7.83 with a high price target of $11.00 and a low price target of $6.00. Learn more on ERAS's analyst rating history.

Do Wall Street analysts like Erasca more than its competitors?

Analysts like Erasca more than other Medical companies. The consensus rating score for Erasca is 2.80 while the average consensus rating score for medical companies is 2.68. Learn more on how ERAS compares to other companies.

Does Erasca's stock price have much upside?

According to analysts, Erasca's stock has a predicted upside of 251.41% based on their 12-month stock forecasts.

What analysts cover Erasca?

Erasca has been rated by Capital One Financial, HC Wainwright, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ERAS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners